AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 27 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A vaccine against human T-cell leukemia/lymphoma virus type 1 (HTLV-1) shows promise in pilot prime-boost regimens.
Mirdad Kazanji at the Pasteur Institute in French Guyana and researchers at private pharmaceutical corporations and the U.S. National Institutes of Health studied the efficacy of two highly attenuated vaccinia virus-derived NYVAC vaccines that encoded either the HTLV-1 env gene or both the env and gag genes in squirrel monkeys. The vaccines were preceded or followed by DNA expressing the HTLV-1 envelope.
"Three inoculations of NYVAC HTLV-1 env at zero, one, and three months followed by a single inoculation of DNA env at nine months protected against intravenous challenge with HTLV-1-infected cells in one of three immunized squirrel monkeys," reported Kazanji and colleagues. The squirrel monkey exhibited both humoral and cell-mediated immunity to HTLV-1 Env, they added.
But, they found better success when they used the env DNA first in a primer inoculation, followed by the NYVAC HTLV-1 gag and env vaccine at six, seven, and eight months. This regimen protected all three animals against subsequent infectious challenge and stimulated antibodies against HTLV-1 env and cell-mediated responses against env and gag ("Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri ...
Source: HighBeam Research, HTLV-1 Vaccine Protects Squirrel Monkeys From Infectious...